{'fraction_non_alphanumeric': 0.015151515151515152, 'fraction_numerical': 0.011961722488038277, 'mean_word_length': 5.121951219512195, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Correction of hypercalcemia in an acute kidney injury patient on continuous renal replacement therapy by the use of commercially available solutions

lating ESA concentration after administration may initiate neocytolysis, and the temporal decrease in serum hemoglobin levels in the current study may be explained by neocytolysis. In patients who underwent Q2W DA administration, a temporal hemoglobin decrease occurred uniformly at day 7, irrespective of DA dose, and at day 7 in patients who underwent Q2W administration of CERA 100 μg/4 weeks. On the other hand, in patients who underwent Q2W administration of CERA 50 μg/ 4 weeks, a temporal decrease in hemoglobin levels was not apparent. The different results in patients with CERA 50 μg/4 weeks compared to the findings in other groups could be explained by a longer half-life of CERA than DA and a relatively small dose; in this situation, a decrease in circulating erythropoietin level occurs slowly. Although the occurrence of neocytolysis is just a speculation and further study is needed, the effect of the difference in the ESA administration interval on anemia may not be exclusively due to the difference in erythropoietic effect, and neocytolysis may partially participate in the process.